首页> 外文期刊>The Lancet >The safety of addition of nitrous oxide to general anaesthesia in at-risk patients having major non-cardiac surgery (ENIGMA-II): A randomised, single-blind trial
【24h】

The safety of addition of nitrous oxide to general anaesthesia in at-risk patients having major non-cardiac surgery (ENIGMA-II): A randomised, single-blind trial

机译:非心脏手术高危患者(ENIGMA-II)在全身麻醉中添加一氧化二氮的安全性:一项随机,单盲试验

获取原文
获取原文并翻译 | 示例
           

摘要

Background Nitrous oxide is commonly used in general anaesthesia but concerns exist that it might increase perioperative cardiovascular risk. We aimed to gather evidence to establish whether nitrous oxide affects perioperative cardiovascular risk.Methods We did an international, randomised, assessor-blinded trial in patients aged at least 45 years with known or suspected coronary artery disease having major non-cardiac surgery. Patients were randomly assigned via automated telephone service, stratified by site, to receive a general anaesthetic with or without nitrous oxide. Attending anaesthetists were aware of patients' group assignments, but patients and assessors were not. The primary outcome measure was a composite of death and cardiovascular complications (non-fatal myocardial infarction, stroke, pulmonary embolism, or cardiac arrest) within 30 days of surgery. Our modified intention-to-treat population included all patients randomly assigned to groups and undergoing induction of general anaesthesia for surgery. This trial is registered at ClinicalTrials.gov, number NCT00430989.Findings Of 10102 eligible patients, we enrolled 7112 patients between May 30, 2008, and Sept 28, 2013. 3543 were assigned to receive nitrous oxide and 3569 were assigned not to receive nitrous oxide. 3483 patients receiving nitrous oxide and 3509 not receiving nitrous oxide were assessed for the primary outcome. The primary outcome occurred in 283 (8%) patients receiving nitrous oxide and in 296 (8%) patients not receiving nitrous oxide (relative risk 0·96, 95% CI 0·83-1·12; p=0·64). Surgical site infection occurred in 321 (9%) patients assigned to nitrous oxide, and in 311 (9%) patients in the no-nitrous oxide group (p=0·61), and severe nausea and vomiting occurred in 506 patients (15%) assigned to nitrous oxide and 378 patients (11%) not assigned to nitrous oxide (p<0·0001).Interpretation Our findings support the safety profile of nitrous oxide use in major non-cardiac surgery. Nitrous oxide did not increase the risk of death and cardiovascular complications or surgical-site infection, the emetogenic effect of nitrous oxide can be controlled with antiemetic prophylaxis, and a desired effect of reduced volatile agent use was shown.Funding Australian National Health and Medical Research Council; Australian and New Zealand College of Anaesthetists; Heart and Stroke Foundation of Quebec, Heart and Stroke Foundation of Ontario, Canada; General Research Fund of the Research Grant Council, Hong Kong Special Administrative Region, China.
机译:背景技术一氧化二氮通常用于全身麻醉,但担心会增加围手术期的心血管风险。我们旨在收集证据来确定一氧化二氮是否会影响围手术期心血管疾病的风险。方法我们对至少45岁,已知或疑似冠心病且患有重大非心脏手术的患者进行了一项国际,随机,评估者盲试验。通过自动电话服务将患者随机分配,按地点分层,以接受含或不含一氧化二氮的全身麻醉。主治麻醉师知道患者的分组情况,但患者和评估者则不知道。主要结果指标是手术后30天内死亡和心血管并发症(非致命性心肌梗塞,中风,肺栓塞或心脏骤停)的综合指标。我们经过修改的意向治疗人群包括所有随机分组并接受全身麻醉以进行手术的患者。该试验已在ClinicalTrials.gov上注册,编号NCT00430989。调查结果在2008年5月30日至2013年9月28日之间的10102名合格患者中,我们招募了7112名患者。3543例接受一氧化二氮,3569例不接受一氧化二氮。 。主要结果评估了3483例接受一氧化二氮和3509例未接受一氧化二氮的患者。主要结局发生在283名(8%)接受一氧化二氮的患者和296名(8%)未接受一氧化二氮的患者中(相对风险0·96,95%CI 0·83-1·12; p = 0·64) 。一氧化二氮的手术部位感染发生在321名患者中(9%),而无一氧化二氮组的手术部位感染中有311名患者(9%)发生(p = 0·61),而506名患者中发生了严重的恶心和呕吐(15) %)被分配给一氧化二氮,378名患者(11%)没有被分配给一氧化二氮(p <0·0001)。解释我们的发现支持在主要的非心脏手术中使用一氧化二氮的安全性。一氧化二氮不会增加死亡和心血管并发症或手术部位感染的风险,可以通过止吐预防来控制一氧化二氮的致呕作用,并显示出减少挥发剂使用的预期效果。澳大利亚国家卫生与医学研究基金会理事会;澳大利亚和新西兰的麻醉师学院;加拿大魁北克心脏与中风基金会,加拿大安大略省心脏与中风基金会;中国香港特别行政区研究补助金理事会普通研究基金。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号